Jump Financial, LLC Morphic Holding, Inc. Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$31.28 - $56.99 $2.49 Million - $4.53 Million	-79,539 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $1.76 Million - $2.3 Million	67,387 Added 554.53%	79,539 $2.71 Million
Q1 2024 May 13, 2024	BUY	$26.64 - $40.31 $323,729 - $489,847	12,152 New	12,152 $427,000
Q3 2023 Oct 21, 2024	BUY	$21.33 - $59.42 $1.1 Million - $3.05 Million	51,396 Added 626.78%	59,596 $1.37 Million
Q3 2023 Nov 07, 2023	BUY	$21.33 - $59.42 $1.27 Million - $3.54 Million	59,596 New	59,596 $1.37 Million
Q1 2023 Oct 21, 2024	SELL	$26.01 - $48.69 $1.86 Million - $3.47 Million	-71,339 Reduced 89.69%	8,200 $308,000
Q1 2023 May 03, 2023	BUY	$26.01 - $48.69 $213,282 - $399,258	8,200 New	8,200 $308,000
Q3 2022 Nov 07, 2022	SELL	$22.23 - $33.37 $95,589 - $143,491	-4,300 Reduced 11.78%	32,200 $911,000
Q2 2022 Aug 09, 2022	BUY	$19.74 - $43.01 $720,510 - $1.57 Million	36,500 New	36,500 $792,000
Q2 2021 Aug 13, 2021	SELL	$45.13 - $64.99 $146,537 - $211,022	-3,247 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $96,663 - $275,507	3,247 New	3,247 $205,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.